Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling
PhasePhase 2/Phase 3
Lead SponsorSomaxon Pharmaceuticals
StatusCompleted No Results Posted
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.
Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
Nalmefene HCl 20 mg
Nalmefene HCl 40 mg
Inclusion Criteria: Current diagnosis of pathological gambling as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)